-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the normalized development of volume-based procurement, major pharmaceutical companies are actively deploying generic drug consistency evaluations
.
According to incomplete statistics in the industry, a total of 84 varieties passed/deemed to have passed the evaluation in April, of which 16 varieties were the first to pass the evaluation, involving companies including Yangzijiang, Kelun Pharmaceutical, Haitong Pharmaceutical, Lianhuan Pharmaceutical, and Hang Seng Pharmaceutical.
, Beite Pharmaceutical, Huachen Pharmaceutical, Hongri Pharmaceutical and more than 10 companies
.
The 16 top-rated varieties include Oxytocin Injection, Doxycycline Hydrochloride Tablets, Tedizolid Phosphate for Injection, Medium and Long Chain Fat Emulsion/Amino Acid (16)/Glucose (36%) Injection, Medium and Long Chain Fat Milk/amino acid (16)/glucose (16%) injection, sugammadex sodium injection, fat milk amino acid (17) glucose (19%) injection,
etc.
Among these varieties, there are many promising varieties, such as tedizolid phosphate, which is a derivative of linezolid.
According to industry statistics, the peak in-hospital sales of linezolid in recent years is about 1.
7 billion, and it will decline in 2021.
, reaching 1.
3 billion
.
The industry believes that the market prospect of tedizolid as its derivative drug is bright
.
At present, the domestic approval of tedizolid phosphate for injection is held by the original research and Yangzijiang Pharmaceuticals.
This time, the Yangzijiang variety has won the first review, which is conducive to improving its market competitiveness
.
In addition to Tedizolid Phosphate for Injection, Yangzijiang also has many varieties such as Shugeng Sodium Glucose Injection, which have won the first review
.
For example, sugammadex sodium is the first selective muscle relaxation antagonist approved for the reversal of neuromuscular blocking agents in the world.
It can help patients with general anesthesia accurately and quickly reverse deep and moderate muscle relaxation during clinical anesthesia surgery.
state, promote the recovery of spontaneous breathing and limb mobility, and help improve the postoperative outcome of patients
.
According to data from Minet.
com, in 2020, the sales of terminal Shugeng Gluconate Sodium Injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have exceeded 170 million yuan, a year-on-year increase.
140.
35%; in the first half of 2021, its sales increased rapidly, which has exceeded the full year of 2020, an increase of 226.
50% over the same period
.
Kelun Pharmaceutical has also reviewed a number of varieties in April, and most of them are injection varieties, including medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection, medium and long chain fat emulsion/amino acid ( 16)/glucose (16%) injection, fat milk amino acid (17) glucose (19%) injection,
etc.
Kelun Pharmaceutical is a research and development and innovation enterprise focusing on the pharmaceutical infusion industry.
Its pharmaceutical industry covers infusion, powder injection, small water injection, tablets, capsules and other dosage forms.
It is a large pharmaceutical group with a complete domestic industrial chain.
.
The company announced in mid-April that the medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection was the company's 13th new product approved in the field of parenteral nutrition.
The company has become a full range of parenteral nutrition system solutions provider
.
The differentiated fat emulsion formula can meet the product selection of patients with different types of clinical (liver function impairment, perioperative period, critical illness, etc.
); products with different amino acid and glucose concentrations can meet the precise parenteral nutrition energy supply for patients with different clinical levels of catabolism Demand; diversified specifications provide more economical parenteral nutrition energy supply methods for patients of different ages, body weights and supplemental parenteral nutrition needs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to incomplete statistics in the industry, a total of 84 varieties passed/deemed to have passed the evaluation in April, of which 16 varieties were the first to pass the evaluation, involving companies including Yangzijiang, Kelun Pharmaceutical, Haitong Pharmaceutical, Lianhuan Pharmaceutical, and Hang Seng Pharmaceutical.
, Beite Pharmaceutical, Huachen Pharmaceutical, Hongri Pharmaceutical and more than 10 companies
.
The 16 top-rated varieties include Oxytocin Injection, Doxycycline Hydrochloride Tablets, Tedizolid Phosphate for Injection, Medium and Long Chain Fat Emulsion/Amino Acid (16)/Glucose (36%) Injection, Medium and Long Chain Fat Milk/amino acid (16)/glucose (16%) injection, sugammadex sodium injection, fat milk amino acid (17) glucose (19%) injection,
etc.
Among these varieties, there are many promising varieties, such as tedizolid phosphate, which is a derivative of linezolid.
According to industry statistics, the peak in-hospital sales of linezolid in recent years is about 1.
7 billion, and it will decline in 2021.
, reaching 1.
3 billion
.
The industry believes that the market prospect of tedizolid as its derivative drug is bright
.
At present, the domestic approval of tedizolid phosphate for injection is held by the original research and Yangzijiang Pharmaceuticals.
This time, the Yangzijiang variety has won the first review, which is conducive to improving its market competitiveness
.
In addition to Tedizolid Phosphate for Injection, Yangzijiang also has many varieties such as Shugeng Sodium Glucose Injection, which have won the first review
.
For example, sugammadex sodium is the first selective muscle relaxation antagonist approved for the reversal of neuromuscular blocking agents in the world.
It can help patients with general anesthesia accurately and quickly reverse deep and moderate muscle relaxation during clinical anesthesia surgery.
state, promote the recovery of spontaneous breathing and limb mobility, and help improve the postoperative outcome of patients
.
According to data from Minet.
com, in 2020, the sales of terminal Shugeng Gluconate Sodium Injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have exceeded 170 million yuan, a year-on-year increase.
140.
35%; in the first half of 2021, its sales increased rapidly, which has exceeded the full year of 2020, an increase of 226.
50% over the same period
.
Kelun Pharmaceutical has also reviewed a number of varieties in April, and most of them are injection varieties, including medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection, medium and long chain fat emulsion/amino acid ( 16)/glucose (16%) injection, fat milk amino acid (17) glucose (19%) injection,
etc.
Kelun Pharmaceutical is a research and development and innovation enterprise focusing on the pharmaceutical infusion industry.
Its pharmaceutical industry covers infusion, powder injection, small water injection, tablets, capsules and other dosage forms.
It is a large pharmaceutical group with a complete domestic industrial chain.
.
The company announced in mid-April that the medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection was the company's 13th new product approved in the field of parenteral nutrition.
The company has become a full range of parenteral nutrition system solutions provider
.
The differentiated fat emulsion formula can meet the product selection of patients with different types of clinical (liver function impairment, perioperative period, critical illness, etc.
); products with different amino acid and glucose concentrations can meet the precise parenteral nutrition energy supply for patients with different clinical levels of catabolism Demand; diversified specifications provide more economical parenteral nutrition energy supply methods for patients of different ages, body weights and supplemental parenteral nutrition needs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
